.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA24_Levonadifloxacin.Levonadifloxacin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA24_Levonadifloxacin.Levonadifloxacin| name: | Levonadifloxacin |
| ATC code: | J01MA24 | route: | intravenous |
| n-compartments | 2 |
Levonadifloxacin is a broad-spectrum, novel benzoquinolizine fluoroquinolone antibiotic used primarily for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired pneumonia. It is effective against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Levonadifloxacin has been approved for clinical use in India.
Pharmacokinetic parameters for healthy adult subjects following intravenous administration.
Bhatia, A, et al., & Friedland, HD (2020). Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. The Journal of the Association of Physicians of India 68(8) 30–36. PUBMED:https://pubmed.ncbi.nlm.nih.gov/32738837